Literature DB >> 24981235

A functional variant at miR-132-3p, miR-212-3p, and miR-361-5p binding site in CD80 gene alters susceptibility to gastric cancer in a Chinese Han population.

Ruirong Wu1, Fuchao Li, Jianjie Zhu, Rong Tang, Qinghua Qi, Xinru Zhou, Rui Li, Weipeng Wang, Dong Hua, Weichang Chen.   

Abstract

A number of single-nucleotide polymorphisms within the 3'-UTR of genes have been shown to relate to the occurrence of cancers. In this study, by using polymerase chain reaction-restriction fragment length analysis method, we determined an SNP rs1599795 in the 3'-UTR of CD80 gene in 183 gastric cancer patients and 348 healthy controls. Statistical analysis results showed that SNP rs1599795 genotypes were significantly correlated with the risk of gastric cancer. Compared with the AA homozygotes, the TA heterozygotes were significantly more prevalent in the patients (OR 1.44, 95 % CI 0.98-2.11) with a larger tumor size (P = 0.001), deeper infiltration (P = 1.5 × 10(-5)), higher possibility of lymph node metastasis (P = 0.003), and more in the late stage (TNM stage III and IV; P = 0.003); the TT homozygotes had larger tumor size (P = 0.001) and lower degree of differentiation (P = 2.2 × 10(-4)). Dual-luciferase reporter assays showed that miR-132-3p, miR-212-3p, and miR-361-5p inhibited the expression of CD80 through binding with the CD80 3'-UTR, and this inhibitory role of miR-132-3p, miR-212-3p, and miR-361-5p was impacted by rs1599795. Our findings have shown that the SNP rs1599795 in CD80 3'-UTR, through disrupting the regulatory role of miR-132-3p, miR-212-3p, and miR-361-5p in CD80 expression, contributed to the occurrence of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24981235     DOI: 10.1007/s12032-014-0060-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  29 in total

1.  A functional variant at miR-24 binding site in B7-H2 alters susceptibility to gastric cancer in a Chinese Han population.

Authors:  Panpan Yang; Rong Tang; Jianjie Zhu; Lingting Zou; Ruirong Wu; Huan Zhou; Yong Mao; Rui Li; Dong Hua; Weipeng Wang; Hongjian Zhang
Journal:  Mol Immunol       Date:  2013-05-18       Impact factor: 4.407

2.  miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor.

Authors:  Jong-Kook Park; Jon C Henry; Jinmai Jiang; Christine Esau; Yuriy Gusev; Megan R Lerner; Russell G Postier; Daniel J Brackett; Thomas D Schmittgen
Journal:  Biochem Biophys Res Commun       Date:  2011-02-15       Impact factor: 3.575

3.  Mucosal immune environment in colonic carcinogenesis: CD80 up-regulation in colonic dysplasia in ulcerative colitis.

Authors:  Marco Scarpa; Marina Bortolami; Attilio Cecchetto; Diego Faggian; Andromachi Kotsafti; Cesare Ruffolo; Filippo Navaglia; Anna Pozza; Renata D'Incà; Mario Plebani; Giacomo C Sturniolo; Imerio Angriman
Journal:  Eur J Cancer       Date:  2010-11-08       Impact factor: 9.162

4.  Expression of costimulatory molecules, B7-1 and B7-2 on human gastric carcinoma.

Authors:  S Koyama; T Maruyama; S Adachi; M Nozue
Journal:  J Cancer Res Clin Oncol       Date:  1998       Impact factor: 4.553

5.  The miR-146a rs2910164 G > C polymorphism and susceptibility to digestive cancer in Chinese.

Authors:  Dong Wu; Fan Wang; Wei-Qi Dai; Lei He; Jie Lu; Ling Xu; Chuan-Yong Guo
Journal:  Asian Pac J Cancer Prev       Date:  2013

6.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

7.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Authors:  Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

Review 8.  MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics.

Authors:  Prasun J Mishra; Pravin J Mishra; Debabrata Banerjee; Joseph R Bertino
Journal:  Cell Cycle       Date:  2008-01-28       Impact factor: 4.534

9.  In situ expression and significance of B7 costimulatory molecules within tissues of human gastric carcinoma.

Authors:  Xiao-Li Chen; Xu-Dong Cao; An-Jing Kang; Kang-Min Wang; Bao-Shan Su; Yi-Li Wang
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

10.  Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation.

Authors:  P S Linsley; W Brady; L Grosmaire; A Aruffo; N K Damle; J A Ledbetter
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

View more
  15 in total

1.  MiR-212-3p inhibits cell proliferation and promotes apoptosis by targeting nuclear factor IA in bladder cancer.

Authors:  Xiaoming Wu; Hao Chen; Gaoyue Zhang; Jianhui Wu; Wei Zhu; Yanqin Gu; Y I He
Journal:  J Biosci       Date:  2019-09       Impact factor: 1.826

2.  MiR-132-3p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11.

Authors:  Baoyu Wu; Jingyu Li; Han Wang; Qian Wu; Hui Liu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-02-10       Impact factor: 3.000

3.  miR-361-5p inhibits glioma migration and invasion by targeting SND1.

Authors:  Jing Liu; Jie Yang; Lin Yu; Chun Rao; Qian Wang; Cuiyun Sun; Cuijuan Shi; Dan Hua; Xuexia Zhou; Wenjun Luo; Run Wang; Weiping Li; Shizhu Yu
Journal:  Onco Targets Ther       Date:  2018-08-28       Impact factor: 4.147

4.  Epithelial CD80 promotes immune surveillance of colonic preneoplastic lesions and its expression is increased by oxidative stress through STAT3 in colon cancer cells.

Authors:  Chiara Marchiori; Melania Scarpa; Andromachi Kotsafti; Susan Morgan; Matteo Fassan; Vincenza Guzzardo; Andrea Porzionato; Imerio Angriman; Cesare Ruffolo; Stefania Sut; Stefano Dall'Acqua; Romeo Bardini; Raffaele De Caro; Carlo Castoro; Marco Scarpa; Ignazio Castagliuolo
Journal:  J Exp Clin Cancer Res       Date:  2019-05-09

Review 5.  MicroRNA-361: A Multifaceted Player Regulating Tumor Aggressiveness and Tumor Microenvironment Formation.

Authors:  Daozhi Xu; Peixin Dong; Ying Xiong; Junming Yue; Kei Ihira; Yosuke Konno; Noriko Kobayashi; Yukiharu Todo; Hidemichi Watari
Journal:  Cancers (Basel)       Date:  2019-08-07       Impact factor: 6.639

6.  miR-196b regulates gastric cancer cell proliferation and invasion via PI3K/AKT/mTOR signaling pathway.

Authors:  N A Li; Weiqiang Wang; Bin Xu; Hongyun Gong
Journal:  Oncol Lett       Date:  2016-01-26       Impact factor: 2.967

7.  Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p.

Authors:  Guoping Ding; Liangjing Zhou; Yingming Qian; Mingnian Fu; Jian Chen; Jionghuang Chen; Jianyang Xiang; Zhengrong Wu; Guixing Jiang; Liping Cao
Journal:  Oncotarget       Date:  2015-10-06

8.  Expression of Smo in pancreatic cancer CD44+CD24+cells and construction of a lentiviral expression vector to silence Smo.

Authors:  Peng Cong; Chao Yi; Xi-Yan Wang
Journal:  Oncol Lett       Date:  2018-08-16       Impact factor: 2.967

9.  miR-195/miR-497 Regulate CD274 Expression of Immune Regulatory Ligands in Triple-Negative Breast Cancer.

Authors:  Lianzhou Yang; Yuchen Cai; Dongsheng Zhang; Jian Sun; Chenyu Xu; Wenli Zhao; Wenqi Jiang; Chunhua Pan
Journal:  J Breast Cancer       Date:  2018-12-26       Impact factor: 3.588

10.  Elevated expression of exosomal microRNA-21 as a potential biomarker for the early diagnosis of pancreatic cancer using a tethered cationic lipoplex nanoparticle biochip.

Authors:  Xiaofan Pu; Guoping Ding; Mingjie Wu; Senhao Zhou; Shengnan Jia; Liping Cao
Journal:  Oncol Lett       Date:  2020-01-15       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.